4th edition new draft.pub - The University of Manchester

4
Studies to recruit to
ESOS (European Scleroderma Observational Study) is a new prospective
observational study comparing treatment outcomes in early diffuse
cutaneous systemic sclerosis (dcSSc). The study is funded as part of
the EULAR Orphan Disease Programme, which aims to improve knowledge
of the pathogenesis and treatment of SSc. It has been accepted onto the
NIHR Portfolio (ID 8799) under the musculoskeletal topic.
ESOS is coordinated by the University of Manchester and will involve
the documentation of current best practice (using a web-based data
collection system) in patients with early dcSSc. The four treatment
protocols being recruited are; methotrexate, mycophenolate mofetil,
cyclophosphamide, and also those receiving no immunosuppressant
treatment. Recruitment started in July 2010 in centres across Europe and
will continue for the next 2 years.
If you have a patient with early dcSSc (defined as within 3 years of the
onset of skin thickening) who might be eligible you can:
Visit the study website: http://www.ssc-esos.net
Or
E-mail the study co-ordinator: holly.ennis@manchester.ac.uk